Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Caloric Restriction Slows Age-Related Loss of Neurons by Activating SIRT1

By BiotechDaily International staff writers
Posted on 06 Jun 2013
Print article
Image: Senior author Dr. Li-Huei Tsai (Photo courtesy of the Massachusetts Institute of Technology).
Image: Senior author Dr. Li-Huei Tsai (Photo courtesy of the Massachusetts Institute of Technology).
Image: To delay the onset of neurodegeneration, mice have the option to undergo a regimen of caloric restriction (represented by the scale) or a pharmacological treatment with a SIRT1-activation compound (tube labeled SRT), both of which result in reduced memory loss and preserved synaptic plasticity (Photo courtesy of Dr. Li-Huei Tsai, Massachusetts Institute of Technology).
Image: To delay the onset of neurodegeneration, mice have the option to undergo a regimen of caloric restriction (represented by the scale) or a pharmacological treatment with a SIRT1-activation compound (tube labeled SRT), both of which result in reduced memory loss and preserved synaptic plasticity (Photo courtesy of Dr. Li-Huei Tsai, Massachusetts Institute of Technology).
Caloric restriction (CR), a dietary regimen known to promote lifespan by retarding the onset of age-dependent diseases, has been found to slow the progressive loss of neurons associated with impaired cognitive capacity by activating the enzyme sirtuin 1 (SIRT1, silent mating type information regulation 2 homolog 1).

Investigators at the Massachusetts Institute of Technology (Cambridge, USA) speculated that since aging is the greatest risk factor for neurodegeneration in the brain, CR might slow the progressive loss of neurons. To explore this possibility they used a genetically engineered mouse model that allowed for temporally and spatially controlled onset of neurodegeneration. These animals were fed a diet decreased by 30% from the normal mouse diet for three months.

Results published in the May 22, 2013, issue of the Journal of Neuroscience revealed that CR significantly delayed the onset of neurodegeneration and synaptic loss and dysfunction, and thereby preserved cognitive capacities.

“We not only observed a delay in the onset of neurodegeneration in the calorie-restricted mice, but the animals were spared the learning and memory deficits of mice that did not consume reduced-calorie diets,” said senior author Dr. Li-Huei Tsai, professor of brain and cognitive sciences at the Massachusetts Institute of Technology. “The question now is whether this type of treatment will work in other animal models, whether it is safe for use over time, and whether it only temporarily slows down the progression of neurodegeneration or stops it altogether



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.